SCHEMBL23330530

SCHEMBL23330530

O=C(CN1CCOCC1)Nc1cnc(Cl)nc1Cl

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.54
▸ GAA P10253 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ TSHR P16473 1/20 0.52
▸ POLB P06746 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ MAPT P10636 1/20 0.49
▸ LMNA P02545 2/20 0.49
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ CLK1 P49759 1/20 0.47
▸ ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330531 0.85 ALDH1A1 (0.50) ALDH1A1GAANPSR1TSHRPOLB
SCHEMBL23330484 0.80 MAPT (0.50) ALDH1A1GAANPSR1TSHRPOLB
SCHEMBL23330522 0.74 ALDH1A1 (0.48) ALDH1A1GAANPSR1TSHRPOLB
SCHEMBL17385135 0.73 MEN1 (0.44) ALDH1A1GAANPSR1TSHRKDM4E
SCHEMBL23331087 0.72 HDAC1 (0.47) KMT2A
SCHEMBL23331244 0.71 P2RX7 (0.43) GAAPOLBSMN1; SMN2KMT2AMEN1
SCHEMBL23519407 0.70 TSHR (0.56) ALDH1A1TSHRSMN1; SMN2LMNAKMT2A
SCHEMBL6819648 0.70 ALDH1A1 (0.77) ALDH1A1GAANPSR1POLBL3MBTL1
SCHEMBL1563869 0.70 TSHR (0.62) ALDH1A1GAANPSR1TSHRPOLB
SCHEMBL23330667 0.70 ABL1 (0.41) ALDH1A1POLBKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 — — US disclosed
WO-2021083380-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海科技大学 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 ALDH1A1 650/4885GAA 982/4885NPSR1 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback